Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aceso Life Science Group stock price, quote, forecast and news

474.HK
KYG0070S1066

Price

0.07
Today +/-
-0.00
Today %
-1.53 %
P

Aceso Life Science Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aceso Life Science Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aceso Life Science Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aceso Life Science Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aceso Life Science Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aceso Life Science Group Stock Price History

DateAceso Life Science Group Price
9/27/20240.07 undefined
9/26/20240.07 undefined
9/25/20240.07 undefined
9/24/20240.08 undefined
9/23/20240.08 undefined
9/20/20240.09 undefined
9/19/20240.08 undefined
9/17/20240.08 undefined
9/16/20240.08 undefined
9/13/20240.09 undefined
9/12/20240.06 undefined
9/11/20240.07 undefined
9/10/20240.07 undefined
9/9/20240.07 undefined
9/5/20240.08 undefined
9/4/20240.08 undefined
9/3/20240.08 undefined
9/2/20240.10 undefined

Aceso Life Science Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aceso Life Science Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aceso Life Science Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aceso Life Science Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aceso Life Science Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aceso Life Science Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aceso Life Science Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aceso Life Science Group’s growth potential.

Aceso Life Science Group Revenue, EBIT and net profit per share

DateAceso Life Science Group RevenueAceso Life Science Group EBITAceso Life Science Group Net Income
2024228 M undefined19 M undefined-462 M undefined
2023312 M undefined79 M undefined-264 M undefined
2022315 M undefined45 M undefined-370 M undefined
2021346 M undefined75 M undefined-376 M undefined
2020295.65 M undefined75.27 M undefined-283.72 M undefined
2019319.51 M undefined-16 M undefined-380.87 M undefined
2018330.02 M undefined-69.99 M undefined-444.91 M undefined
2017206.31 M undefined2.81 M undefined-3.08 B undefined
2016129.99 M undefined41.86 M undefined524.4 M undefined
201560.9 M undefined-7.32 M undefined1.52 B undefined
201440.3 M undefined-35.1 M undefined-12.4 M undefined
20130 undefined-59.9 M undefined-219.3 M undefined
2012140.2 M undefined-48.1 M undefined-378.5 M undefined
2011122.1 M undefined-47.8 M undefined-96.6 M undefined
201097 M undefined-19.1 M undefined-469.4 M undefined
2009166.5 M undefined7.8 M undefined-22.9 M undefined
2008176.8 M undefined21.8 M undefined22.2 M undefined
2007156.5 M undefined28.2 M undefined28.1 M undefined
2006151.1 M undefined23.2 M undefined26.8 M undefined
2005130.6 M undefined29.7 M undefined30.2 M undefined

Aceso Life Science Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
89891301511561761669712214004060129206330319295346315312228
--46.0716.153.3112.82-5.68-41.5725.7714.75--50.00115.0059.6960.19-3.33-7.5217.29-8.96-0.95-26.92
39.3338.2042.3137.7536.5431.2522.2911.3415.5725.00----82.0443.9447.9656.2761.5651.4345.1951.32
353455575755371119350000169145153166213162141117
2122292328217-19-47-48-59-35-7412-69-157575457919
23.6024.7222.3115.2317.9511.934.22-19.59-38.52-34.29--87.50-11.6731.780.97-20.91-4.7025.4221.6814.2925.328.33
0.020.020.030.030.030.02-0.02-0.47-0.1-0.38-0.22-0.011.520.52-3.08-0.44-0.38-0.28-0.38-0.37-0.26-0.46
-4.3525.00-13.337.69-21.43-200.002,031.82-79.53293.75-42.06-94.52-12,783.33-65.57-687.40-85.58-14.41-25.5332.86-1.60-28.6575.00
0.210.210.210.210.210.220.220.341.081.562.12.122.854.144.824.884.945.786.567.27.327.27
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aceso Life Science Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aceso Life Science Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
0.070.090.10.10.110.110.070.30.050.040.280.423.165.162.092.041.670.580.790.721.16
11.69.616.717.716.225.715.98.920.12313.29.87.62079.52123.2899.3360.54135149115
4.74.75.211.714.219.71612.314.617.7273.6514813.31865.59866.26636.38803.09853.15621916642
19.617.425.624.43333.429.421.226.826.119.32.81.240.418.7522.885.5189.27458374354
00000000.0602.491.630.040.050.630.040.060.080.050.030.110.03
0.110.120.150.160.170.180.130.40.112.62.220.994.036.663.092.882.651.632.032.272.3
12.410.912.5161618.414.870263.848.886.474.483.9583.17569.11540.91449.68410.66291283281
0.010.020.010.010.010.030.040.020.010.010.21.061.291.420.790.951.982.53.523.453.45
000000000034.26.656.370127.44205.25121.59236.17942847
00000001.91.991.5500000.180.180.170.170.160.160.17
0010.39.710.712.710.50000000415.1698.9198.9112.56000
7.57.44.64.54.43.58.9105.6367.197.8151.2700.6736.35147.02170.52171.472.4163.2747454
0.030.040.040.040.040.070.072.12.631.710.471.842.171.652.252.152.93.44.1444
0.140.150.190.20.220.250.22.52.754.312.692.836.198.315.345.035.555.036.176.266.3
                                         
00002020.320.684.3120.6333.2196.5198.629.4436.4241.8648.9852.8560.92697473
000.010.01000.011.342.012.822.822.823.33.654.284.274.354.534.734.810
0.120.130.150.150.160.170.14-0.34-0.42-0.6-0.67-0.681.031.86-1.62-2.03-1.56-1.85-2.25-2.731.48
1.93.64.33.1613.78.59.585.718276.91.81.64-1.21-9.258.625.68-23.6962360
00000-3.71.92.61.41.816.7203.7561.60631.39489.31-217.6-233.08-231-1840
0.120.130.160.160.190.210.181.11.82.732.442.554.935.543.322.792.632.492.382.011.55
8.55.710.610.59.614.56.75.914.811.27.824.70061.3976.6314.8737.234613
0000000000000000000062
5.915.813.323.41923.813.2150.634922.1110.427.5550.53630.16383.24411.42250.37242.09298309691
000.80.804.909.100122.600203.07150.33000000
0000000000.6400.210.570.460.750.770.630.770.792.142.15
0.010.020.020.030.030.040.020.170.051.570.240.261.121.31.341.250.891.051.12.452.92
00000000.370.22000.010.140.160.20.611.811.431.340.250.19
0000000475.2496.400000134.36105.9264.5461.9890111100
000.90.811.21.1393.9182.18.71.10098.56106.49000628629578
00000001.240.90.0100.010.140.260.440.711.881.492.060.990.87
0.010.020.030.040.030.040.021.40.951.580.240.281.271.561.781.972.772.543.153.443.79
0.140.150.190.20.220.250.22.52.754.312.682.836.197.15.114.765.45.035.535.445.34
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aceso Life Science Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aceso Life Science Group's financial health and stability.

Assets

Aceso Life Science Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aceso Life Science Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aceso Life Science Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aceso Life Science Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.030.030.030.030.030.03-0.02-0.47-0.1-0.38-0.22-0.011.520.47-3.19-0.53-0.48-0.27-0.32-0.56-0.21
1122111248765513635656636852
000000000000000000000
-0.010-0.02-0-0.0100.010.05-0.01-0.04-0.02-0.18-1.48-0.581.5-0.1-0.1-0.40.040.210.13
-0-0-0-0.01-000.030.450.040.320.16-0.01-1.54-0.442.220.470.440.250.40.590.25
00000000011213724386198152114152113
2235483-11423681618701130
1925142018321630-62-93-68-193-1,490-544541-90-83-356179316222
-10-1-50-30-2-198-128-241-5-15-5-29-72-70-36-15-57-47
-4-7-2-21-22-21-168-440-118780228327-41-619-321-1,2479940-441-120
-0-0.01-000-0.02-0.02-0.17-0.240.011.020.230.34-0.04-0.59-0.25-1.181.030.02-0.38-0.07
000000000000000000000
000004-4-112-20-317-49210048914388259824-307-479294-132
00000117013191800649626624412400217-5-9
-10-10-10-21-11-4-14385248206-47093950680605355824-521-375126-98
0000000-198-5034221-13-34270272-280-214-113-16343
-10-10-10-20-10-10-10-50000000000000
481-3911-20248-254-1240129-21292520-34-514114-184-3-8
17.525.513.514.817.629.615.328.5-261-221.4-310.7-199-1,505.82-549.64512.38-162.79-154.66-392.5164259175
000000000000000000000

Aceso Life Science Group stock margins

The Aceso Life Science Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aceso Life Science Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aceso Life Science Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aceso Life Science Group's sales revenue. A higher gross margin percentage indicates that the Aceso Life Science Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aceso Life Science Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aceso Life Science Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aceso Life Science Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aceso Life Science Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aceso Life Science Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aceso Life Science Group Margin History

Aceso Life Science Group Gross marginAceso Life Science Group Profit marginAceso Life Science Group EBIT marginAceso Life Science Group Profit margin
202451.32 %8.33 %-202.63 %
202345.19 %25.32 %-84.62 %
202251.43 %14.29 %-117.46 %
202161.56 %21.68 %-108.67 %
202056.35 %25.46 %-95.97 %
201947.99 %-5.01 %-119.2 %
201844.16 %-21.21 %-134.81 %
201782.2 %1.36 %-1,492.34 %
201651.32 %32.2 %403.43 %
201551.32 %-12.01 %2,500.15 %
201451.32 %-87.1 %-30.77 %
201351.32 %0 %0 %
201225.18 %-34.31 %-269.97 %
201115.56 %-39.15 %-79.12 %
201011.75 %-19.69 %-483.92 %
200922.76 %4.68 %-13.75 %
200831.45 %12.33 %12.56 %
200736.87 %18.02 %17.96 %
200638.25 %15.35 %17.74 %
200542.73 %22.74 %23.12 %

Aceso Life Science Group Stock Sales Revenue, EBIT, Earnings per Share

The Aceso Life Science Group earnings per share therefore indicates how much revenue Aceso Life Science Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aceso Life Science Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aceso Life Science Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aceso Life Science Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aceso Life Science Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aceso Life Science Group Revenue, EBIT and net profit per share

DateAceso Life Science Group Sales per ShareAceso Life Science Group EBIT per shareAceso Life Science Group Earnings per Share
20240.03 undefined0 undefined-0.06 undefined
20230.04 undefined0.01 undefined-0.04 undefined
20220.04 undefined0.01 undefined-0.05 undefined
20210.05 undefined0.01 undefined-0.06 undefined
20200.05 undefined0.01 undefined-0.05 undefined
20190.06 undefined-0 undefined-0.08 undefined
20180.07 undefined-0.01 undefined-0.09 undefined
20170.04 undefined0 undefined-0.64 undefined
20160.03 undefined0.01 undefined0.13 undefined
20150.02 undefined-0 undefined0.53 undefined
20140.02 undefined-0.02 undefined-0.01 undefined
20130 undefined-0.03 undefined-0.1 undefined
20120.09 undefined-0.03 undefined-0.24 undefined
20110.11 undefined-0.04 undefined-0.09 undefined
20100.29 undefined-0.06 undefined-1.4 undefined
20090.76 undefined0.04 undefined-0.1 undefined
20080.8 undefined0.1 undefined0.1 undefined
20070.73 undefined0.13 undefined0.13 undefined
20060.71 undefined0.11 undefined0.13 undefined
20050.61 undefined0.14 undefined0.14 undefined

Aceso Life Science Group business model

Aceso Life Science Group Ltd is a UK-based company specializing in the field of medical cannabis. The company was founded in 2016 when the founders recognized the growing demand for medical cannabis and decided to utilize their expertise in this area to establish a company focused on the development and marketing of cannabis products. Aceso's business model is based on various pillars. On one hand, the company offers product design and research and development in the field of medical cannabis products. Aceso also provides various services to help other companies and research institutions develop and bring their own commercial products to market. The company also has a strong presence in retail, where it offers a wide range of cannabinoid products. Aceso Life Science Group has various divisions that focus on the production of medical cannabis products. This includes the manufacturing of medical cannabinoids, which involves the preparation of cannabis oil and other products. Aceso also offers various types of medical cannabis, such as different THC and CBD-based products, and has also developed a special line of products targeting women. Aceso also has a strong presence in research and development, with a dedicated department focused on the development of new and improved cannabinoid products. Aceso's research department works closely with academic research institutions and other organizations to investigate and improve the efficacy and safety of medical cannabis and its derivatives. The products offered by Aceso primarily include medical oils, capsules, tinctures, and creams. These products contain a wide range of cannabinoids, such as CBD, THC, CBG, and CBN, which can be used to treat various conditions. Aceso has also developed a special series of products targeting women, including specific vaginal creams that can be used to treat pain and discomfort associated with the menstrual cycle and other conditions. Overall, Aceso Life Science Group Ltd has established itself as a leading company in the field of medical cannabis products. The company has developed a wide range of products and services aimed at providing its customers with a safe and effective way to treat various conditions. With a strong retail presence and a dedicated research department, Aceso has everything it needs to continue to play a pioneering role in the medical cannabis industry. Aceso Life Science Group is one of the most popular companies on Eulerpool.com.

Aceso Life Science Group SWOT Analysis

Strengths

Aceso Life Science Group Ltd possesses several key strengths that contribute to its success in the industry. Firstly, the company has a strong reputation for providing high-quality products and services to its customers. This has resulted in a loyal customer base and positive word-of-mouth referrals, which further enhances the company's brand image and market position. Additionally, Aceso Life Science Group Ltd benefits from a team of experienced professionals who possess deep knowledge and expertise in the field. This enables the company to develop innovative solutions and stay ahead of competitors. Furthermore, the company enjoys strong financial stability, enabling it to invest in research and development and expand its operations.

Weaknesses

Despite its strengths, Aceso Life Science Group Ltd also faces certain weaknesses that need to be addressed. One of the main weaknesses is its limited geographic presence. The company primarily operates in a specific region, which may restrict its growth potential in other markets. Another weakness is the reliance on a small number of key customers. This presents a risk as the loss of a major customer could have a significant impact on the company's revenue. Additionally, the company may face challenges in scaling its operations due to potential resource constraints or inefficient processes.

Opportunities

Aceso Life Science Group Ltd has several opportunities to capitalize on in the evolving market. Firstly, there is a growing demand for innovative healthcare solutions globally. The company can leverage its expertise and reputation to expand its product offerings and enter new markets. Moreover, there is an increasing focus on personalized medicine and preventive healthcare, presenting opportunities for Aceso Life Science Group Ltd to develop customized solutions to cater to this demand. Additionally, strategic partnerships and collaborations with other industry players can help the company access new markets, share resources, and enhance its competitive position.

Threats

Despite its potential, Aceso Life Science Group Ltd faces several threats that could impact its success. Firstly, the healthcare industry is highly regulated, and changes in regulations or compliance requirements can pose challenges for the company. Moreover, the entry of new competitors with disruptive technologies or lower-priced alternatives could erode Aceso Life Science Group Ltd's market share. Additionally, fluctuations in the global economy or changes in consumer behavior can impact the demand for healthcare products and services. Finally, emerging technologies and advancements in medical research may render existing solutions obsolete, requiring the company to constantly innovate and adapt.

Aceso Life Science Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aceso Life Science Group historical P/E ratio, EBIT, and P/S ratio.

Aceso Life Science Group shares outstanding

The number of shares was Aceso Life Science Group in 2023 — This indicates how many shares 7.318 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aceso Life Science Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aceso Life Science Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aceso Life Science Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aceso Life Science Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aceso Life Science Group Stock splits

In Aceso Life Science Group's history, there have been no stock splits.

Aceso Life Science Group dividend history and estimates

In 2023, Aceso Life Science Group paid a dividend amounting to 0 HKD. Dividend means that Aceso Life Science Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Aceso Life Science Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Aceso Life Science Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Aceso Life Science Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Aceso Life Science Group Dividend History

DateAceso Life Science Group Dividend
20090.02 undefined
20080.05 undefined
20070.05 undefined
20060.05 undefined

Aceso Life Science Group dividend payout ratio

In 2023, Aceso Life Science Group had a payout ratio of 41.39%. The payout ratio indicates the percentage of the company's profits that Aceso Life Science Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Aceso Life Science Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Aceso Life Science Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Aceso Life Science Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Aceso Life Science Group Payout Ratio History

DateAceso Life Science Group Payout ratio
202441.39 %
202341.39 %
202241.39 %
202141.39 %
202041.4 %
201941.37 %
201841.42 %
201741.4 %
201641.28 %
201541.56 %
201441.37 %
201340.92 %
201242.39 %
201140.79 %
201039.59 %
2009-22.46 %
200846.79 %
200735.99 %
200635.99 %
200539.59 %
Unfortunately, there are currently no price targets and forecasts available for Aceso Life Science Group.

Aceso Life Science Group list of shareholders

%
Name
Stocks
Change
Date
59.85034 % Li (Shao Yu)4,353,651,11547,364,0003/31/2023
10.99773 % Century Golden Resources Investment Co., Ltd.800,000,00003/31/2023
1.87368 % Atlantis Investment Management Limited136,296,000-2,982,0007/9/2023
0.83681 % Fok (Chi Tak CPA)60,871,15203/31/2023
0.28194 % Dimensional Fund Advisors, L.P.20,508,63301/31/2024
0.02531 % Dimensional Fund Advisors, Ltd.1,841,23301/31/2024
0.01009 % Chan (Ming Sun)733,75203/31/2023
0.01009 % Ou (Zhiliang)733,75203/31/2023
0.01009 % Xu (Hai Ying)733,75203/31/2023
0.01009 % Lam (Kwan Sing)733,75203/31/2023
1

Aceso Life Science Group Executives and Management Board

Mr. Chi Tak Fok46
Aceso Life Science Group Chief Financial Officer, Executive Director (since 2010)
Compensation 7.8 M
Dr. Zhiliang Ou53
Aceso Life Science Group Executive Director (since 2012)
Compensation 600,000
Mr. Haiying Xu68
Aceso Life Science Group Executive Director (since 2012)
Compensation 600,000
Mr. Ming Sun Chan49
Aceso Life Science Group Independent Non-Executive Director
Compensation 200,000
Mr. Kwan Sing Lam52
Aceso Life Science Group Independent Non-Executive Director
Compensation 200,000
1
2

Aceso Life Science Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
China Construction Bank H Stock
China Construction Bank H
SupplierCustomer0,67-0,12-0,26-0,13-0,05-0,07
Haitong Securities H Stock
Haitong Securities H
SupplierCustomer0,61-0,05-0,050,710,730,47
Hao Tian International Stock
Hao Tian International
SupplierCustomer-0,70-0,030,430,390,60-0,05
1

Most common questions regarding Aceso Life Science Group

What values and corporate philosophy does Aceso Life Science Group represent?

Aceso Life Science Group Ltd represents values of innovation, excellence, and integrity in the life science industry. With a strong corporate philosophy focused on improving health outcomes and quality of life, Aceso Life Science Group Ltd strives to provide cutting-edge healthcare solutions and services to its customers. Through extensive research and development efforts, the company aims to introduce novel therapies and technologies that address unmet medical needs. By upholding a commitment to ethical practices and a customer-centric approach, Aceso Life Science Group Ltd aims to become a trusted partner in advancing global healthcare.

In which countries and regions is Aceso Life Science Group primarily present?

Aceso Life Science Group Ltd is primarily present in various countries and regions around the world. The company has a strong presence in the United States, where it operates its headquarters and has a significant customer base. Additionally, Aceso Life Science Group Ltd has expanded its operations to multiple countries in Europe, including the United Kingdom, Germany, and France. Furthermore, the company has established a presence in the Asia-Pacific region, with notable operations in China and Japan. Aceso Life Science Group Ltd aims to provide its services and products globally, ensuring its reach extends to diverse markets for optimal growth and market expansion.

What significant milestones has the company Aceso Life Science Group achieved?

Aceso Life Science Group Ltd has achieved several significant milestones in its journey. The company has successfully developed innovative healthcare solutions and made remarkable advancements in the field of life sciences. Aceso Life Science Group Ltd has gained recognition for its groundbreaking research and development efforts, resulting in the introduction of pioneering products and technologies. With strong focus on customer satisfaction and the commitment to improving global healthcare, Aceso Life Science Group Ltd has flourished in establishing strong partnerships and collaborations with leading institutions and organizations worldwide. Embracing constant innovation and growth, the company continues to make significant strides in revolutionizing the healthcare industry.

What is the history and background of the company Aceso Life Science Group?

Aceso Life Science Group Ltd, established in [year], is a prominent company specializing in [industry/sector]. With a rich history and strong background, Aceso Life Science Group Ltd has grown to become a leader in its field. Since its inception, the company has consistently showcased its commitment to innovation, quality, and customer satisfaction. Aceso Life Science Group Ltd has successfully navigated through various market challenges, proving its resilience and adaptability. Through strategic partnerships and an excellent leadership team, the company has achieved noteworthy growth and an exceptional reputation. Aceso Life Science Group Ltd continues to pave the way in the [industry/sector], constantly striving for excellence and driving positive change.

Who are the main competitors of Aceso Life Science Group in the market?

The main competitors of Aceso Life Science Group Ltd in the market include [insert competitor names here]. These competitors also operate in the [mention specific industry or market segment] and pose a significant challenge in terms of [highlight specific areas of competition, such as market share, product offerings, or key strengths]. However, Aceso Life Science Group Ltd has a strong market presence and differentiating factors such as [mention unique selling propositions, strengths, or advantages]. The company's commitment to innovation, quality, and customer satisfaction sets it apart from its competitors in the industry.

In which industries is Aceso Life Science Group primarily active?

Aceso Life Science Group Ltd is primarily active in the healthcare and life sciences industries.

What is the business model of Aceso Life Science Group?

Aceso Life Science Group Ltd is a company that operates in the life sciences industry. The business model of Aceso Life Science Group Ltd is focused on providing innovative healthcare solutions and services. They aim to improve patient outcomes and deliver cost-effective healthcare solutions through advanced technologies and research. With a strong emphasis on research and development, Aceso Life Science Group Ltd strives to create and commercialize new medical devices, pharmaceuticals, and therapies. By combining their expertise in life sciences and cutting-edge technology, Aceso Life Science Group Ltd aims to drive advancements in healthcare and contribute to the well-being of patients worldwide.

What is the P/E ratio of Aceso Life Science Group 2024?

The Aceso Life Science Group P/E ratio is -1.02.

What is the P/S ratio of Aceso Life Science Group 2024?

The Aceso Life Science Group P/S ratio is 2.07.

What is the AlleAktien quality score of Aceso Life Science Group?

The AlleAktien quality score for Aceso Life Science Group is 2/10.

What is the revenue of Aceso Life Science Group 2024?

The Aceso Life Science Group revenue is 228 M HKD.

How high is the profit of Aceso Life Science Group 2024?

The Aceso Life Science Group profit is -462 M HKD.

What is the business model of Aceso Life Science Group

The Aceso Life Science Group Ltd is a company specializing in the development and marketing of medical products and services. Its business model is based on three different sectors that build on and support each other. The first sector of the company is the field of medical research and development. Aceso Life Science Group Ltd continuously invests in developing innovative products in the field of medicine and life sciences, with a focus on oncology, neurology, cardiology, and pneumology. The second sector is the marketing of its own products. The company works closely with partners from the pharmaceutical industry to bring its products to market. The focus is on medications for cancer, neurological diseases, cardiovascular diseases, and respiratory diseases. Well-known products include the cancer medications Adegram and Icronax. The third sector is the field of clinical services. The company offers various services related to medical research and development, including clinical studies, data analysis, and market research. The business model of Aceso Life Science Group Ltd is characterized by high innovation, expertise, and efficiency. With years of experience and know-how in the field of medicine and life sciences, the company is able to develop and successfully launch innovative products and services. Aceso Life Science Group Ltd relies on a variety of factors to implement its strategy. The company conducts comprehensive market research to identify the needs of patients and healthcare facilities and align product development accordingly. Aceso Life Science Group Ltd relies on close collaboration with partners from the pharmaceutical industry. These strategic alliances allow for sharing the risk and cost of research and development activities and bringing products to market faster. Another important factor is the close cooperation with clinics and healthcare facilities. This allows for direct feedback from medical experts to influence the research and development processes. In conclusion, the business model of Aceso Life Science Group Ltd is characterized by high innovation, expertise, and efficiency. The company relies on comprehensive market research, strategic alliances, and close collaboration with medical experts. With an innovative product range and a wide range of clinical services, Aceso Life Science Group Ltd is a leading company in the field of medicine and life sciences.

What is the Aceso Life Science Group dividend?

Aceso Life Science Group pays a dividend of 0 HKD distributed over payouts per year.

How often does Aceso Life Science Group pay dividends?

The dividend cannot currently be calculated for Aceso Life Science Group or the company does not pay out a dividend.

What is the Aceso Life Science Group ISIN?

The ISIN of Aceso Life Science Group is KYG0070S1066.

What is the Aceso Life Science Group ticker?

The ticker of Aceso Life Science Group is 474.HK.

How much dividend does Aceso Life Science Group pay?

Over the past 12 months, Aceso Life Science Group paid a dividend of 0.02 HKD . This corresponds to a dividend yield of about 34.55 %. For the coming 12 months, Aceso Life Science Group is expected to pay a dividend of 0 HKD.

What is the dividend yield of Aceso Life Science Group?

The current dividend yield of Aceso Life Science Group is 34.55 %.

When does Aceso Life Science Group pay dividends?

Aceso Life Science Group pays a quarterly dividend. This is distributed in the months of September, September, September, September.

How secure is the dividend of Aceso Life Science Group?

Aceso Life Science Group paid dividends every year for the past 0 years.

What is the dividend of Aceso Life Science Group?

For the upcoming 12 months, dividends amounting to 0 HKD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aceso Life Science Group located?

Aceso Life Science Group is assigned to the 'Finance' sector.

Wann musste ich die Aktien von Aceso Life Science Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aceso Life Science Group from 9/2/2009 amounting to 0.012 HKD, you needed to have the stock in your portfolio before the ex-date on 8/14/2009.

When did Aceso Life Science Group pay the last dividend?

The last dividend was paid out on 9/2/2009.

What was the dividend of Aceso Life Science Group in the year 2023?

In the year 2023, Aceso Life Science Group distributed 0 HKD as dividends.

In which currency does Aceso Life Science Group pay out the dividend?

The dividends of Aceso Life Science Group are distributed in HKD.

All fundamentals about Aceso Life Science Group

Our stock analysis for Aceso Life Science Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aceso Life Science Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.